Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor has been approved by FDA for patients with pancreatic cancer and non-small cell lung cancer. Skin rash is a well-known side effect related with all EGFR blocking agents. It has been suggested that rash could be used as a surrogate marker for response and possibly be associated with prolonged survival. There is scant data reporting bacteremia secondary to severe erlotinib skin toxicity. In this letter, we report a case that developed systemic bacteremia while on erlotinib for treatment of advanced pancreatic cancer due to development of severe rash. This case underlines the significance of potential severe/systemic infection associated with erlotinib. Previously there are many reports describing various skin toxicity manifestation, however, this is the second case in English literature which had systemic Staphylococcus aureus bacteremia arising from erlotinib skin toxicity. Monitor patients closely after starting EGFR blocking agents and initiate immediate skin care based on general guideline are highly recommended.
Download full-text PDF |
Source |
---|
Topical formulations containing 5-Fluorouracil (5-FU) have been proven effective in preventing the proliferation of skin cancer cells. However, their use is linked to side effects such as inflammatory and allergic reactions. Dexamethasone (Dexa) is a synthetic glucocorticoid used across allergic reactions which can be useful in preventing the 5-FU side effects.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
School of Veterinary Medicine, Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, PR China; Joint International Research Laboratory of Agriculture and Agri-Product Safety, the Ministry of Education of China, Yangzhou University, Yangzhou, Jiangsu 225009, PR China. Electronic address:
Bacterial-infected wounds usually lead to slow wound healing due to increased inflammation, especially wounds infected by drug-resistant bacteria, which is a serious challenge in the biomedical field. Traditional antimicrobial strategies such as antibiotics lead to a significant increase in drug-resistant strains and have limited efficacy. Therefore, there is an urgent need to develop multifunctional dressings with excellent antibacterial activity and promotion of wound healing.
View Article and Find Full Text PDFTarget Oncol
January 2025
Division of Hematology and SCT, Georgia Cancer Centre, Augusta, GA, USA.
Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML resistant or intolerant to prior therapy. Clinical trials have shown bosutinib is effective as first-line therapy for patients with CML as well as in later lines of therapy after prior TKI failure. Bosutinib has an established safety profile; however, as with all TKIs approved for the treatment of CML, there are adverse events (AEs) that require management.
View Article and Find Full Text PDFSci Rep
January 2025
Faculty of Biotechnology, October University for Modern Sciences and Arts (MSA), 6th of October City, Egypt.
Nanotherapy has emerged as a promising strategy for the targeted and efficient treatment of melanoma, the most aggressive and lethal form of skin cancer, with minimized systemic toxicity. However, the therapeutic efficacy of cobalt oxide nanoparticles (CoONPs) in melanoma treatment remains unexplored. This study aimed to assess the therapeutic potential of CoONPs in melanoma treatment by evaluating their impact on cell viability, genomic DNA and mitochondrial integrity, reactive oxygen species (ROS) generation and apoptosis induction in melanoma A-375 cells.
View Article and Find Full Text PDFCurr Pharm Biotechnol
January 2025
School of Physiotherapy and Rehabilitation, Jamia Hamdard University, India.
Cosmeceutical products such as skin-lightening agents have been used globally to enhance skin tone and obtain a magnificent outward appearance. The pigment known as melanin, produced by melanocytes, imparts skin color. The Cosmetic Europe survey testifies that most people believe that cosmetics enhance one's quality of life.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!